AHA Scientific Sessions 2026 Abstract · Nov 2, 2026

Efficacy of Enlicitide on LDL-C Reduction Across PREVENT Cardiovascular Risk Categories in the Phase 3 CORALreef Lipids Study

By Navar AM, KC W, Banka P et al.

Background: The AHA Predicting Risk of cardiovascular disease EVENTs (PREVENT) is a guideline-endorsed cardiovascular risk tool used to estimate 10-year risk and guide lipid-lowering therapy decisions, particularly in primary prevention settings. A substantial proportion of patients with high risk of a first ASCVD event are above the guideline-recommended thresholds for LDL-C and additional treatment options are needed. Enlicitide, an oral inhibitor of PCSK9, has demonstrated robust LDL-C lowering of approximately 60% in Phase 3 studies, and has the potential to offer another therapeutic option for patients. Research Questions: This analysis focused on the subset of participants in the Phase 3 CORALreef Lipids study who were at risk for a first major ASCVD event and had baseline data available to calculate PREVENT risk scores. The objective was to assess whether the efficacy of enlicitide is consistent across different cardiovascular risk strata. Methods: Baseline PREVENT 10-year risk was categorized as low (<3%), borderline (3-<5%), intermediate (5-<10%), or high (≥10%) risk. Week 24 percent change from baseline in LDL-C was assessed across PREVENT risk categories. Additional analyses evaluated percent change in apoB, Lp(a), and non-HDL-C, as well as LDL-C goal attainment. Results: A total of 843 participants (573 enlicitide, 270 placebo) were included in the analysis. Baseline PREVENT risk categories were 8.2% low, 18.3% borderline, 44.0% intermediate, and 29.5% high risk. As PREVENT risk increased from low to high, mean age increased from 48.8 to 70.4 years, the proportion of men increased from 37.7% to 53.4%, diabetes prevalence increased from 59.4% to 83.5%, and antihypertensive use increased from 33.3% to 88.0%. Racial composition was similar across strata, although the proportion of Asian participants decreased (23.2% to 16.9%) and Black or African American participants increased (7.2% to 10.8%) with higher risk. Baseline LDL-C was similar across strata (95.6-107.2 mg/dL), and most participants were receiving moderate- or high-intensity statin therapy. At week 24, placebo-corrected mean percent changes from baseline in LDL-C were -62.6% in low risk, -57.6% in borderline risk, -57.1% in intermediate risk, and -58.0% in high risk PREVENT strata. Reductions in apoB, Lp(a), and non-HDL-C were also observed across strata (Figure). LDL-C goal attainment (i.e., LDL-C <70 mg/dL) was higher with enlicitide across all risk categories versus placebo. Conclusions: Enlicitide provided consistent LDL-C lowering across baseline PREVENT cardiovascular risk categories with corresponding reductions in apoB, Lp(a), and non-HDL-C. These findings support the efficacy of enlicitide across a broad range of cardiovascular risk profiles and reinforce its potential role in primary prevention.

doi.org/10.1161/circ.154.suppl_1.11512Interventions

AgingResearch.News